IL1B and neoplasm: Thus, while IL-1β-induced MDSCs in response to chemotherapy support pro-tumorigenic activity, it is possible that the effects are mostly associated with resistance to chemotherapy at the primary tumor site, where the blockade of IL-1β following chemotherapy may increase pro-metastatic biological processes.